CMPX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CM

Mkt Cap

$156.5M

Volume

1.50M

Next Earnings

November 4th

Loading chart

CM

CMPXCompass Therapeutics, Inc. Common Stock

CMPX

Pay with—

Available Balance0.00

CM

Mkt Cap

$161.5M

Volume

1.50M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026Compass Therapeutics announced that its abstract for tovecimig, a DLL4 x VEGF-A bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will showcase Phase 2/3 COMPANION-002 trial results evaluating tovecimig combined with paclitaxel in patients with advanced biliary tract cancer, to be presented by Dr. Nilofer Azad from Johns Hopkins University on October 24, 2026.GlobeNewswire Inc. · Jul 17, 2026

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingCompass Therapeutics announced Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showing promising monotherapy activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The drug demonstrated deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with a 33% overall response rate at the highest dose levels and no dose-limiting toxicities observed.GlobeNewswire Inc. · May 21, 2026

Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesJohnson Fistel, PLLP is investigating potential securities law violations by Compass Therapeutics following the disclosure that its lead drug candidate tovecimig failed to meet the overall survival secondary endpoint in the COMPANION-002 clinical trial. The company reported median overall survival of 8.9 months versus 9.4 months for the control arm, resulting in significant stock price decline. Investors who suffered losses are encouraged to contact the firm.GlobeNewswire Inc. · Apr 27, 2026

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract CancerCompass Therapeutics will host a webcast on April 27, 2026 to present topline secondary endpoints from its Phase 2/3 COMPANION-002 study evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody combined with paclitaxel, in patients with advanced biliary tract cancer. The study has reached its prespecified event threshold of 80% overall survival events.GlobeNewswire Inc. · Apr 24, 2026

Compass Therapeutics to Participate in Upcoming December Investor EventsCompass Therapeutics announced participation in two healthcare investor conferences in December 2025, highlighting their ongoing clinical-stage oncology research focused on antibody-based therapeutics targeting tumor growth and immune system interactions.GlobeNewswire Inc. · Nov 25, 2025

Compass Therapeutics to Participate in Upcoming September Investor EventsCompass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.GlobeNewswire Inc. · Aug 26, 2025

Compass Therapeutics Announces Pricing of Upsized $120 Million Public OfferingCompass Therapeutics plans to raise approximately $120 million through a public offering of 33,290,000 common stock shares and pre-funded warrants at $3.00 per share, with the proceeds intended for research, clinical development, and corporate purposes.GlobeNewswire Inc. · Aug 13, 2025

Compass Therapeutics Announces Proposed Public OfferingCompass Therapeutics plans to launch an underwritten public offering of common stock and pre-funded warrants to fund research, clinical development, and commercial readiness preparations.Benzinga · Aug 12, 2025

Top 3 High-Momentum Companies Analysts Are Still Bullish OnThree companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.Investing.com · Feb 4, 2025

Compass Therapeutics to Participate in Upcoming Investor EventsCompass Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in September 2024, where it will present updates on its oncology-focused pipeline of antibody-based therapeutics.GlobeNewswire Inc. · Sep 3, 2024

to start trading

CM

CMPXCompass Therapeutics, Inc. Common Stock

CMPX

Pay with—

Available Balance0.00

Your PositionYou don't own any CMPX yet.

Related Tickers

Earnings